Alentis Therapeutics, a pioneering clinical-stage biotechnology company specializing in Claudin-1 (CLDN1) innovations, proudly announces the successful raise of $2,500,000 in funding. This critical investment empowers Alentis to advance its mission of developing first-in-class antibodies and antibody-drug conjugates (ADCs) aimed at combating CLDN1+ tumors and organ fibrosis—conditions that currently lack effective treatment options. By targeting CLDN1, a novel biomarker implicated in a variety of malignancies and fibrotic diseases, Alentis is uniquely positioned in the healthcare landscape as the only company focused on transforming the therapeutic approach to solid tumors and fibrotic conditions.
Alentis’ robust portfolio features groundbreaking candidates, including their lead oncology asset, ALE.C04, designed to reprogram the tumor microenvironment (TME) and enhance immune responses against solid tumors. Furthermore, the company's investigational therapy ALE.F02, currently in Phase 1 clinical trials, represents a promising treatment for advanced organ fibrosis, targeting the pathological overexpression of CLDN1 in vital organs like the kidney, lung, and liver. Founded in 2019, Alentis is the fruit of cutting-edge research spearheaded by Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Headquartered in Basel, Switzerland, with an R&D subsidiary in France, Alentis Therapeutics is committed to reshaping the future of cancer and fibrosis treatment. For more information on our innovative therapies and ongoing research, please visit us at www.alentis.ch or reach out via email at info@alentis.ch.
